Oncolytics Biotech Inc. Files 6-K with Incorporated Information Circular
Ticker: ONCY · Form: 6-K · Filed: Aug 8, 2025 · CIK: 1129928
Sentiment: neutral
Topics: regulatory-filing, registration-statement, incorporation-by-reference
TL;DR
Oncolytics Biotech filed a 6-K on Aug 8, 2025, referencing an earlier info circular for their F-10 registration.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on August 8, 2025, incorporating by reference an Information Circular from a previous filing on July 8, 2025. This circular is part of their Registration Statement on Form F-10 (File No. 333-281009).
Why It Matters
This filing indicates ongoing regulatory activity and the incorporation of previously disclosed information into a broader registration statement, which is relevant for investors tracking the company's compliance and financial reporting.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previously disclosed information, not announcing new material events.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- August 8, 2025 (date) — Filing date
- July 8, 2025 (date) — Date of incorporated Information Circular
- Form F-10 (document) — Registration Statement
- 333-281009 (document) — File number for Form F-10
- Form 6-K (document) — Filing type
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to incorporate by reference Exhibit 99.1, an Information Circular, into Oncolytics Biotech Inc.'s Registration Statement on Form F-10.
When was this Form 6-K filed?
This Form 6-K was filed on August 8, 2025.
What document is being incorporated by reference?
An Information Circular, previously filed as Exhibit 99.1 to the registrant's Foreign Issuer Report on Form 6-K on July 8, 2025, is being incorporated by reference.
What is the file number for the Registration Statement on Form F-10?
The file number for the Registration Statement on Form F-10 of Oncolytics Biotech Inc. is 333-281009.
Is Oncolytics Biotech Inc. a foreign private issuer?
Yes, the filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 for a Report of Foreign Private Issuer.
Filing Stats: 204 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-08-08 08:46:39
Filing Documents
- tm2522910d1_6k.htm (6-K) — 10KB
- 0001104659-25-075499.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) Date: August 8, 2025 By: /s/ Kirk Look Kirk Look Chief Financial Officer